Goodrx Holdings, Inc.

Technology
EDP Services
www.goodrx.com

Earnings Score
Moat Score
Safety Score

Market Cap $1.83B
PE -113
Debt $491.34M
Cash $423.78M
EV $1.89B
FCF $153.53M

Earnings

loading chart...

Sales & Net Margins

loading chart...

Earnings	-$16.22M
EBIT	$29.38M
ROE	-2%
ROA	2%
FCF	$153.53M
Equity	$696.43M
Growth Stability	1
PE	-112.6
PEG	29.63
PB	2.62
P/FCF	11.89
P/S	2.31
Price/Cash	0.23
Debt/Equity	0.71
Debt/FCF	3.2
Net Margins	2%
Gross Margins	94%
Op. Margins	4%
Earnings CAGR	-2%
Sales Growth YoY	8%
Sales Growth QoQ	-3%
Sales CAGR	11%
FCF CAGR	8%
Equity CAGR	-2%
Earnings Stability	-0.52
Earnings Growth YoY	-110%
Earnings Growth QoQ	-41%

Earnings CAGR 5Y	-4%
Sales CAGR 5Y	12%
FCF CAGR 5Y	9%
Equity CAGR 5Y	-2%
Earnings CAGR 3Y	-0%
Sales CAGR 3Y	-0%
FCF CAGR 3Y	-7%
Equity CAGR 3Y	-7%
Market Cap	$1.83B
Revenue	$790.39M
Assets	$1.35B
Total Debt	$491.34M
Cash	$423.78M
Shares Outstanding	379.67M
EV	1.89B
Earnings Score	6%
Moat Score	29%
Safety Score	90%
Final Score	42%
Working Capital	512.44M
Current Ratio	5.48
Gross Profit	$739.19M
Shares Growth 3y	-3%
Equity Growth QoQ	4%
Equity Growth YoY	-21%

Assets & ROA

loading chart...

Stockholders Equity & ROE

loading chart...

GoodRx is a consumer-focused digital healthcare platform that aims to lower the cost of healthcare in the United States. It has over 6 million active monthly users. The company's primary focus is the U.S. prescription drug market, where GoodRx has developed a price comparison tool that it aggregates from over 200 billion daily pricing data points, directing consumers toward coupons negotiated between a pharmacy and intermediaries (pharmacy benefit managers ). GoodRx generates revenue by taking a small share of the fees paid by pharmacies to PBMs in exchange for routing consumers to these discount programs, and separately through a subscription-based model (GoodRx Gold), which offers discounted drugs to customers paying a monthly membership fee.

SEC Filings

Direct access to Goodrx Holdings, Inc. (GDRX) Annual Reports (10K) and Quarterly Reports (10Q) from the SEC website.

2024
- 10-Q Sep 30
- 10-Q Jun 30
- 10-Q Mar 31
2023
- 10-K Dec 31
- 10-Q Sep 30
- 10-Q Jun 30
- 10-Q Mar 31
2022
- 10-K Dec 31
- 10-Q Sep 30
- 10-Q Jun 30
- 10-Q Mar 31

Sector Comparison

How does Goodrx Holdings, Inc. compare to its competitors?

Loading chart...

Peter Lynch's Chart

This chart shows the current pricing of Goodrx Holdings, Inc. compared to its past. The addition of the earnings trend line provides further insights into the company's earnings power.

CAGR -2%

Stability -52%

loading chart...

Goodrx Holdings, Inc. Discounted Cash Flow

Fully customizable DCF calculator online for Goodrx Holdings, Inc..

Years

Calculation mode

= $2.7B

	0	1	2	3	4	5	6	7	8	9	10	TV
fcf	$154M	$166M	$179M	$194M	$209M	$226M	$245M	$264M	$286M	$309M	$334M	$3.3B
DCF		$151M	$148M	$146M	$143M	$141M	$138M	$136M	$133M	$131M	$129M	$1.3B
Value	$2.7B

Competitiveness and MOAT

High margins render the company resilient under dire circumstances, hence able to drive competitors out or acquire them. ROE and ROA measure the average flow generated by each invested dollar. Their marginal value is a forecast of future growth, and it is considered by Buffett and Munger the most important single indicator.

Years	12/2018	12/2019	12/2020	12/2021	12/2022	12/2023	TTM
Net Margins	6%	11%	-53%	-3%	-4%	-1%	2%
ROA	-	36%	-19%	1%	0%	-2%	2%
ROE	-	-4%	-41%	-3%	-4%	-1%	-2%

Bad Net Margins (1.63%)

Net Margins are too low to guarantee profitability in case of higher costs or higher interest rates. Furthermore lower margins cause higher earnings’ volatility.

Safety and Stability

Being debt the number one cause of investment losses and company death, the ratio Debt/FCF is of utmost importance to guarantee safety. On the other hand the Graham’s stability measures the drawdown of earnings, hence indicating the reliability of the flow generated by the company.

Years	12/2018	12/2019	12/2020	12/2021	12/2022	12/2023	TTM
Debt over FCF	-	8.28	6.21	3.91	4.72	4.78	3.2
Debt over Equity	-	-0.62	0.97	0.82	0.83	0.86	0.71
Growth Stability	-	-	-	-	-	-	1

Neutral Debt/FCF ratio (3.2)

Net Margins are at a level that is not too high nor too low. They are not a competitive advantage but they are not a competitive disadvantage either.

Good Debt/Equity ratio (0.71)

The company is not overleveraged and has a good balance between equity and debt.

Good Graham’s Stability (1)

The company has a good stability in its earnings, which is a sign of a good competitive advantage.

Growth

Growth can be dangerous when forecasting, simply projecting the current growth is in general wrong. A company passes through multiple phases, from being young and unprofitable, to the first periods of profitability and high growth, until it arrives at a period of regime with limited growth. Identifying in which phase the company is in may help forecasting.

Years	12/2018	12/2019	12/2020	12/2021	12/2022	12/2023	CAGR 5Y
Revenue YoY growth	-	56%	42%	35%	3%	-2%	12%
Earnings YoY growth	-	208%	-792%	-91%	30%	-73%	-4%
Equity YoY growth	-	-6%	-165%	17%	-2%	-6%	-2%
FCF YoY growth	-	84%	35%	57%	-18%	-4%	9%